What is the level of liabilities of Innoviva this year?
Innoviva has a debt balance of 568.55 M USD this year.
Innoviva Liabilities 2024
Innoviva Liabilities
568.55 M USD
Ticker
INVA
ISIN
US45781M1018
WKN
A2AC9U
In 2024, Innoviva's total liabilities amounted to 568.55 M USD, a -14.59% difference from the 665.7 M USD total liabilities in the previous year.
Innoviva Aktienanalyse
What does Innoviva do?
Innoviva Inc - An innovative story Innoviva Inc is a US-based company specializing in the development and marketing of therapy and diagnostic products for respiratory diseases. The company was founded in 1996 under the name Theravance Inc and was renamed Innoviva Inc in 2016. The story of Innoviva Inc began with the goal of developing innovative therapies for chronic respiratory diseases. Over the years, the company expanded and diversified its product portfolio. Today, Innoviva Inc is a leading provider of products for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Business model of Innoviva Inc The business model of Innoviva Inc is based on the development of products for the treatment of respiratory diseases and collaboration with other pharmaceutical and biotech companies. The company licenses its products to partner companies, which distribute them in the market. This way, Innoviva Inc generates revenue from licensing fees and milestone payments. Divisions of Innoviva Inc Innoviva Inc is divided into three divisions: development, licensing, and financing. The development division is responsible for researching and developing new therapy and diagnostic products. The company works closely with other pharmaceutical and biotech companies in this regard. The licensing division is responsible for licensing products to partner companies. This includes negotiating license agreements and conducting clinical trials. The financing division of Innoviva Inc is responsible for raising external capital. This includes issuing bonds and seeking investment. Products of Innoviva Inc Innoviva Inc has a wide range of therapy and diagnostic products for respiratory diseases. These include: - RELVAR®/BREO® (Fluticasone furoate/Vilanterol) for the treatment of COPD and asthma - ANORO® (Umeclidinium bromide/Vilanterol) for the treatment of COPD - TRELEGY® (Fluticasone furoate/Umeclidinium bromide/Vilanterol) for the treatment of COPD These products have been developed by Innoviva Inc and are licensed to partner companies for distribution. Innoviva Inc is an innovative company specializing in the development and marketing of products for the treatment of respiratory diseases. The business model is based on the development of products and licensing them to partner companies. Innoviva Inc has a wide range of therapy and diagnostic products for respiratory diseases. Innoviva ist eines der beliebtesten Unternehmen auf Eulerpool.com.Liabilities Details
Assessing Innoviva's Liabilities
Innoviva's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Innoviva's financial stability, operational efficiency, and long-term viability.
Year-to-Year Comparison
By comparing Innoviva's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.
Impact on Investments
Innoviva's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.
Interpreting Liability Fluctuations
Shifts in Innoviva’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.
Frequently Asked Questions about Innoviva stock
What were the liabilities of Innoviva compared to the previous year?
The liabilities of Innoviva have increased by -14.59% dropped compared to the previous year.
What are the consequences of high debt for investors of Innoviva?
High liabilities can pose a risk for investors of Innoviva, as they can weaken the company's financial position and impair its ability to meet its obligations.
What consequences do low liabilities have for investors in Innoviva?
Low liabilities mean that Innoviva has a strong financial position and is able to meet its obligations without overburdening its finances.
How does an increase in liabilities of Innoviva affect the company?
An increase in liabilities of Innoviva can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.
How does a reduction in the liabilities of Innoviva affect the company?
A decrease in the liabilities of Innoviva can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.
What are some factors that influence the liabilities of Innoviva?
Some factors that can influence the liabilities of Innoviva include investments, acquisitions, operating costs, and sales development.
Why is the level of liabilities of Innoviva so important for investors?
The liabilities of Innoviva are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.
What strategic measures can Innoviva take to modify the liabilities?
To change its liabilities, Innoviva can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.
How much dividend does Innoviva pay?
Over the past 12 months, Innoviva paid a dividend of 0.75 USD . This corresponds to a dividend yield of about 3.79 %. For the coming 12 months, Innoviva is expected to pay a dividend of 0 USD.
What is the dividend yield of Innoviva?
The current dividend yield of Innoviva is 3.79 %.
When does Innoviva pay dividends?
Innoviva pays a quarterly dividend. This is distributed in the months of December, April, July, October.
How secure is the dividend of Innoviva?
Innoviva paid dividends every year for the past 0 years.
What is the dividend of Innoviva?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Innoviva located?
Innoviva is assigned to the 'Health' sector.
Wann musste ich die Aktien von Innoviva kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Innoviva from 9/30/2015 amounting to 0.25 USD, you needed to have the stock in your portfolio before the ex-date on 9/8/2015.
When did Innoviva pay the last dividend?
The last dividend was paid out on 9/30/2015.
What was the dividend of Innoviva in the year 2023?
In the year 2023, Innoviva distributed 0 USD as dividends.
In which currency does Innoviva pay out the dividend?
The dividends of Innoviva are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Innoviva stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von Innoviva
Our stock analysis for Innoviva Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Innoviva Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
